Our findings suggest that patients with mild COVID-19 who developed MOG-ON also exhibited a high incidence of an abnormal antiphospholipid antibody spectrum, indicating that even a mild case of COVID-19 may trigger a positive antiphospholipid antibody response, which could potentially serve as a marker for subsequent ON or even MOG-ON. Here, MOG is linked to COVID-19.